Hyperphenylalaninemia is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Hyperphenylalaninemia have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Hyperphenylalaninemia compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Hyperphenylalaninemia overview
Abnormally elevated levels of phenylalanine (PHE) in the blood if >2mg/dl or 120 µmol/L is known as Hyperphenylalaninemia. It is an autosomal-recessive disorder of the phenylalanine (Phe) metabolism and is the most common amino acid metabolism defect in humans. Phenylketonuria is the severe form of HPA. Dietary management is advised if the condition is mild and treatment is necessary in severe cases.
For a complete picture of PTSR and LoA scores for drugs in Hyperphenylalaninemia, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
